Expanded Access Protocol (Eap) For Subjects Receiving Idecabtagene Vicleucel That Is Nonconforming

This study is designed to provide patients access to their nonconforming ide-cel as a treatment option for their disease. The study will evaluate the safety and effectiveness of this therapy through the collection of information. You may or may not receive direct medical benefit from participating in this study. The hope is that this study treatment may provide a new treatment option for patients with your disease, however, such a benefit cannot be guaranteed. There are no study specific procedures required for this study as you will receive routine medical care during the course of your participation. Results from these routine medical care procedures will be collected for research purposes.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  multiple myeloma
• Age: Between 18 Years - 99 Years
• Gender: All